NCI Trials for April

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – 10126

A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

City of Hope Comprehensive Cancer Center LAO

Herrera, Alex Francisco

(626) 256-4673 x 62405

Phase I – 10130

A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors and B-Cell Lymphomas with Hepatic Dysfunction

University Health Network Princess Margaret Cancer Center LAO

Renouf, Daniel John

(604) 877-6000

Phase I – 10131

A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Smyth, Lillian Mary

(646) 888-4894

Phase II – 10129

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Yale University Cancer Center LAO

LoRusso, Patricia Mucci

(203) 785-5944

Phase II – EA2165

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

ECOG-ACRIN Cancer Research Group

Rajdev, Lakshmi

(718) 405-8404

Phase II – S1701

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

SWOG

Tsao, Anne S.

(713) 792-6363

Phase II – S1712

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Yale University Cancer Center LAO

LoRusso, Patricia Mucci

(203) 785-5944

Phase II – 10129

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

SWOG

Sweet, Kendra

(813) 745-6841

Phase Other – AALL17B10-Q

DNA Methylation Stochasticity in Pediatric Acute Lymphoblastic Leukemia

Children’s Oncology Group

Koldobskiy, Michael A.

(410) 614-5055

Phase Other – AALL17B9-Q

The Genetics of Relapsed and Refractory T-Acute Lymphoblastic Leukemia (T-ALL)

Children’s Oncology Group

Ferrando, Adolfo A.

(212) 851-4611

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.

January 31, 2025

Vol.51 No.04

By Paul Goldberg

Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services.

January 31, 2025

Vol.51 No.04

By Claire Marie Porter

Guest Editorial

Our challenge: To find zen in chaos

This column is a love letter of sorts to our field, a recognition of all that we have accomplished and an acknowledgement that we need to find a path forward that supports and empowers the best of what it is to invest in cancer research.

January 31, 2025

Vol.51 No.04

By W. Kimryn Rathmell

Guest Editorial

Foundations acquire a critical new role as federal funding for cancer research falters

The fight against cancer is complex. It’s global. And it’s indisputably expensive.

January 31, 2025

Vol.51 No.04

By Ryan Schoenfeld and Raymond N. DuBois

Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies.

January 31, 2025

Vol.51 No.04

By Ze’ev Ronai

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.

January 31, 2025

Vol.51 No.04

By Yiqing Wang and Jacquelyn Cobb